Immuneering Corporation Class A Common Stock (IMRX)
Immuneering Corporation Class A (IMRX) is a biotechnology company focused on developing therapies for complex neurological and oncology diseases. Founded with the goal of translating computational biology and data-driven insights into innovative treatments, Immuneering leverages its proprietary platform to identify and advance novel drug candidates. The company aims to accelerate drug discovery and improve patient outcomes through its expertise in genomics, computational models, and clinical development.
Company News
Immuneering Corporation will host a conference call to discuss updated overall survival and safety data from a Phase 2a clinical trial of atebimetinib + mGnP in first-line pancreatic cancer patients, with 9 months median follow-up.
Immuneering Corporation announced a public offering of 18,959,914 Class A common stock shares at $9.23 per share, raising approximately $175 million. Simultaneously, Sanofi will purchase 2,708,559 shares in a private placement transaction.
Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors.
Immuneering is ready to share information regarding its lead therapy.